Risk factor
Resilient to price shocks
Profitability factor
Very low or no dividends
About
Vimian Group AB (publ) operates as a global enterprise in the animal health sector, segmenting its business into Specialty Pharma, MedTech, Diagnostics, and Veterinary Services. Through its Nextmune brand, the company delivers a comprehensive portfolio of proprietary diagnostic tools and both prescription and non-prescription therapies designed for the preventive care and ongoing management of chronic conditions in companion animals. The Indical Bioscience division provides specialized molecular and immunodiagnostic solutions, predominantly employed by laboratories for veterinary-specific applications across both livestock and companion animal health markets. Additionally, the VetFamily brand runs a membership-based platform that furnishes veterinary clinics with crucial procurement services, technology-enabled operational support (including online marketing, education, and human resources), and fosters a professional community. Finally, Movora is responsible for supplying orthopedic implants to veterinarians and academic institutions. Founded in 2020, Vimian Group's headquarters are located in Stockholm, Sweden.
Company Valuation
Based on key historical and expected multiples, the stock is slightly overvalued relative to its peers. Specifically, the stock is 'expensive' on P/E, neutral on EV/EBITD
Target Price
The average target price of VIMIAN.ST is 37.2 and suggests 9.07% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation